OncoMatch/Clinical Trials/NCT06340737
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Is NCT06340737 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CD22CART Infusion for follicular lymphoma.
Treatment: CD22CART Infusion — This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and duration of response (DOR). An evaluable participant is one who completes leukapheresis, lymphodepleting chemotherapy and CART infusion.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Hairy Cell Leukemia
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: CD22 expression at any level (any)
CD22 expression, at any level: Participants must have archival tissue available for analysis of CD22 expression or must be willing to undergo biopsy of easily accessible disease.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody combined with systemic therapy
Prior therapy must have included an anti-CD20 monoclonal antibody combined with systemic therapy (single-agent anti-CD20 antibody does not count as line of therapy for eligibility nor does local radiation). Anti-CD20 antibody is not required for participants with CD20 negative disease.
Lab requirements
Blood counts
ANC ≥ 750/uL; Platelet count ≥ 50,000/uL; ALC ≥ 150/uL
Kidney function
Creatinine < 2 mg/dL OR Creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 45 mL/min
Liver function
Serum ALT or AST ≤ 10 x ULN (except in participants with liver involvement by lymphoma), Total bilirubin ≤ 1.5 mg/dl, except in participants with Gilbert's syndrome
Cardiac function
Cardiac left ventricular ejection fraction ≥ 45%, no evidence of clinically significant pericardial effusion as determined by an Echocardiogram
Adequate organ and marrow function as defined by: ANC ≥ 750/uL; Platelet count ≥ 50,000/uL; ALC ≥ 150/uL; Creatinine < 2 mg/dL OR Creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 45 mL/min, Serum ALT or AST ≤ 10 x ULN (except in participants with liver involvement by lymphoma), Total bilirubin ≤ 1.5 mg/dl, except in participants with Gilbert's syndrome, Cardiac left ventricular ejection fraction ≥ 45%, no evidence of clinically significant pericardial effusion as determined by an Echocardiogram. No clinically significant pleural effusion or ascites. Baseline oxygen saturation > 92% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Palo Alto, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify